COAGHemab Therapeutics Holdings Inc. Common Stock
49.16USD-4.84%Mkt Cap: 2.30B $P/E: —3d ago
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap2.30B $
Enterprise Value1.80B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-63.91M $
Revenue/Share—
Last Price49.16 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-19.00
PEG—
EV/EBITDA-20.66
EV/Revenue—
P/S—
P/B4.96
EPS (TTM)-1.67
EPS (Forward)-2.54
52W Range
23.0081% of range55.42
52W High55.42 USD
52W Low23.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE36.18%
ROA-32.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-61.48M $
CapEx (TTM)16.00K $
FCF Margin—
FCF Yield—
Net Debt-456.43M $
Net Debt/EBITDA5.25
Balance Sheet
Debt/Equity-0.01
Current Ratio35.85
Quick Ratio35.48
Book Value/Sh9.726 USD
Cash/Share9.793 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)61.20 USD
Upside (mean)+24.5%
Target Range58.00 USD – 65.00 USD
$58.00+24.5% to mean$65.00
# Analysts5
Ownership
Shares Out.46.71M
Float23.61M
Insiders10.78%
Institutions91.54%
Short Interest
Short Ratio5.0d
Short % Out.4.36%
Shares Short1.66M
Short (prev mo.)1.71M
Technical
SMA 5041.03 (+19.8%)
SMA 20036.05 (+36.4%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)382.80K
Avg Vol (10d)261.55K
Technical Indicators
RSI (14)52.5
MACD2.4955
MACD Signal3.3016
MACD Hist.-0.8061
BB Upper55.98 USD
BB Middle49.99 USD
BB Lower44.01 USD
BB Width23.95%
ATR (14)4.089 USD
Vol Ratio (20d)1.00x